ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how the rules link it today.

5 links0 made here, not in the record7 judgments1 judge (the rules as one: Rule based)0 record changes seen
Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06620822Efficacy of PD-1 InhibitorCombination Therapy inNon-small Cell Lung CancerPatients Who Have NotAchieved Major PathologicResponse After NeoadjuvantImmunotherapy: aShanghai Pulmonary Hospital, SPhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSAnti-PD-1/IL-2 Bispecific A…Entry “IBI363”, read by our name rule›As of now · Rule based · TestedTestedCafelkibartEntry “LM-108+Sintilimab”, read by ou…›As of now · Rule based · TestedTestedSintilimabEntry “LM-108+Sintilimab”, read by ou…›As of now · Rule based · TestedAs of now · Rule based · TestedAs of now · Rule based · ComparatorComparatorAnti-CTLA-4 Monoclonal Anti…Entry “IBI310+Sintilimab”, read by ou…›As of now · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Carcinoma, Non-Small-Cell Lung

From the registry record1 judgment on this link
Main condition (R9), from the registry to what was judged
RegistryCarcinoma, Non-Small-Cell Lung, as filedthe registry files the study under it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent
As of nowAnti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363Rule based · role ruleTestedCurrent
As of nowCafelkibartRule based · role ruleTestedCurrent
As of nowSintilimabRule based · role ruleTestedCurrent
As of nowSintilimabRule based · role ruleTestedCurrent
As of nowSintilimabRule based · role ruleComparatorCurrent
As of nowAnti-CTLA-4 Monoclonal Antibody IBI310Rule based · role ruleTestedCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.